Impressive Bleeding Profile With Factor XI Inhibitor in AF :

Further details from the phase 2b AZALEA trial of the factor XI inhibitor abelacimab show significant reductions in major and clinically relevant nonmajor bleeding vs rivaroxaban for patients with AF.

Related Keywords

Boston , Massachusetts , United States , North Carolina , Philadelphia , Pennsylvania , Duke University , American , John Alexander , Manesh Patel , American Heart Association , Christian Ruff , Scientific Sessions , Exploratory Efficacy Endpoints , Medscape Cardiology , Atrial Fibrillation , F Atrial Fibrillation , Anticoagulation Therapy , Anticoagulant , Anticoagulation , Thromboembolism , Stroke , Erebrovascular Accident , Va Cerebrovascular Accident , Hemorrhage , Bleeding , Embolism , Thrombus , Venous Thromboembolism , Blood Vessels , Arteries , Blood , Boards , Smle , Grant , Heart , Hospitals , Infarct , Infarction , Injury , Ischemic Stroke , Monoclonal Antibody , Etuximab ,